Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Two Cognitive Tests for MS Have Different Strengths

Appl Neuropsychol Adult; ePub 2018 Apr 4; Costa, et al

The California Learning Verbal Test II (CVLT II) and the Open Trial-Selective Reminding Test (OT-SRT), used to assess learning in persons with multiple sclerosis (MS), are not equivalent tests, according to a recent comparison study. While the CVLT II appears to be sensitive to overall cognitive dysfunction, the OT-SRT is more sensitive to focal learning and memory impairments. 112 participants with MS performed both tests. All completed additional cognitive tests assessing information processing speed (IPS), working memory (WM), and executive functions (EF). All participants were identified as having impaired learning on the OT-SRT; however, only 38 participants (33.9%) were identified as having impaired learning on the CVLT II. The sample was thus divided into 2 groups, those who failed both tests (Fail-2) and those who failed only 1 (Fail-1). Researchers found:

  • The Fail-2 group showed poorer performance on EF, WM and IPS in comparison with the Fail-1 group.
  • On the CVLT II, the Fail-1 group showed a significantly greater improvement between trials 1 and 5, as compared with the Fail-2 group.

Citation:

Costa SL, DeLuca J, Costanza K, Chiaravalloti ND. Comparing the open trial – Selective reminding test results with the California Learning Verbal Test II in multiple sclerosis. [Published online ahead of print April 4, 2018]. Appl Neuropsychol Adult. doi:10.1080/23279095.2018.1448818.

This Week's Must Reads

Recurrent Stroke Risk Higher for Blacks than Whites, Neurology; ePub 2018 Oct 3; Albright, Huang, et al

Sleep Duration/Stroke Link Differs by Race and Sex, Neurology; ePub 2018 Oct 3; Petrov, Howard, et al

Intracerebral Hemorrhage Survivors’ Outcomes Studied, J Stroke Cerebrovasc Dis; ePub 2018 Sep 28; Griauzde, et al

Probable OSA Common in Refractory Epilepsy, Epilepsia; ePub 2018 Sep 24; McCarter, et al

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

Must Reads in Multiple Sclerosis

Aerobic Exercise May Improve Cognition in MS, Mult Scler Relat Disord; ePub 2018 Oct 3; Sandroff, et al

Project ECHO Delivers MS Care in Underserved Areas, Int J MS Care; ePub 2018 Oct 4; Alschuler, et al

Use of eHealth Technologies Common in MS Community, Mult Scler Relat Disord; ePub 2018 Oct 3; Marrie, et al

Probability Discounting of MS Treatment Decisions, Psychopharmacology; ePub 2018 Sep 22; Bruce, et al

ADSTEP May Increase Walking in Persons with MS, Arch Phys Med Rehab; 2018 Oct; Martini, et al